伊伐布雷定联合β受体阻滞剂治疗射血分数减低慢性心力衰竭的临床效果

Clinical effect of ivabradine combined withβ-blocker in the treatment of chronic heart failure with decreased ejection fraction

目的:探讨伊伐布雷定联合β受体阻滞剂治疗射血分数(EF)减低慢性心力衰竭的临床效果。方法:选取2019年1月~2020年1月住院的EF值下降慢性心力衰竭患者60例,按随机抽签法分为治疗组30例和对照组30例。对照组给予包括利尿剂、β受体阻滞剂或ARB类、洋地黄类等血管扩张剂治疗。治疗组在此基础上加用伊伐布雷定治疗3个月。应用SPSS软件对患者临床症状、血压、心率、化验氨基末端B型利钠肽前体(NT-pro-BNP)、左心室射血分数(LVEF)等指标前后分析对比,观察应用后伊伐布雷定的疗效。结果:治疗组患者NT-pro-BNP、血压、心率等指标明显低于对照组,射血分数明显高于对照组,差异有统计学意义(P<0.05)。结论:超极激活阳离子钙通道抑制剂-伊伐布雷定作为一种特异性的降低心率药物,能够有效减少冠心病患者的心血管事件,对于控制心率、抗心力衰竭作用确切,对于使用β受体阻滞剂不能耐受患者效果尤其明显,值得推广应用。

Objective To investigate the clinical effect of ivabradine combined withβ-blocker in the treatment of chronic heart failure.Method From January 2019 to January 2020,60 patients with chronic heart failure were randomly divided into treatment group(30 cases)and control group(30 cases)according to random draw.The control group was treated with vasodilators including diuretics,β-blockers,captopril(ACEI)or valsartan(ARB),Cediland,digoxin and mononitrate.The treatment group was treated with ivabradine for 3 months.SPSS software was used to compare the clinical symptoms,blood pressure,heart rate,NT Pro BNP and LVEF of patients before and after the application of ivabradine.The curative effect of ivabradine was observed.Results The NT-Pro-BNP,blood pressure,heart rate and other indexes in the treatment group were significantly lower than those in the control group,and the ejection fraction was significantly higher than that in the control group(P<0.05).Conclusion As a specific heart rate lowering drug,ivabradine can effectively reduce cardiovascular events in patients with coronary heart disease.It has definite effect on heart rate control and anti heart failure,especially in patients who can't tolerateβ-receptor blocker.It is worth popularizing and applying.